Pay in 4 interest-free payments of $5.14 Learn more
Ships within 48 hours · Estimated delivery Oct 5 - Oct 10
Contact us for a free consultation to discuss your legal options.
Taste receptors of the gut: emerging roles in health and disease
Merck and others are developing GLP-1s (MK-8521, orforglipron licensing, etc.), but as of 2026 none have announced capacity builds because their products are not yet commercial
According to McKinseys analysis, 61% of GLP-1 patients seeking aesthetic treatment had lost 11-30% of their body weight, highlighting how significant weight reduction directly correlates with the desire for surgical skin removal
Tanaka K, Sasayama T, Irino Y, Takata K, Nagashima H, Satoh N, Kyotani K, Mizowaki T, Imahori T, Ejima Y, Masui K, Gini B, Yang H, Hosoda K, Sasaki R, Mischel PS, Kohmura E
Although CAR-T therapy demonstrated huge possiblity for the treatment of cancers with high efficiency, compelling challenges still exist regarding the feasibility of this therapy for severe immune deficiency and other cytotoxicity caused by its "on-target, off-tumor" effect [172, 173]
